Clinical Trial Update: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Pf-06651600 for rheumatoid arthritis with inadequate response to methotrexate has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• PF-06651600 (PF-06651600)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-04